Company Overview of Hovione FarmaCiencia SA
Hovione FarmaCiencia SA develops and manufactures active pharmaceutical ingredients (APIs) and intermediate drug products for the pharmaceutical industry in the United States and other North American countries, Europe, and Japan. The company specializes in chemistry and particle engineering. It offers services related to the development, manufacture, and pre-formulation of new chemical entities and existing APIs for off-patent products; NavStream, a read only Internet based management tool that enables selective access to GMP data referent to development project or production line at Hovione; and project management services. The company also provides custom synthesis services in the areas of...
Founded in 1959
Key Executives for Hovione FarmaCiencia SA
Chief Executive Officer and Director
Chief Financial Officer and Vice President of Finance
Vice President of Exclusives & Particle Design Business Units and President of US Operations
Head of Particle Design Sciences In New Jersey
Vice President of Technical Operations
Compensation as of Fiscal Year 2013.
Hovione FarmaCiencia SA Key Developments
Hovione FarmaCiencia SA Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-05-2013 10:30 AM
Oct 24 13
Hovione FarmaCiencia SA Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-05-2013 10:30 AM. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria.
Hovione Presents at BioPharm America 2013, Sep-18-2013 02:15 PM
Sep 17 13
Hovione Presents at BioPharm America 2013, Sep-18-2013 02:15 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.
European Patent Office Grants Patent for Hovione's XCaps, a Dry Powder Inhaler
Sep 11 13
Hovione announced that the European Patent Office has granted a patent for Hovione's XCaps, a dry powder inhaler (DPI). XCaps addresses a pulmonary inhalation market need for a very inexpensive device which combines high efficiency in powder dispersion with ease of use. Lung fractions in excess of 70% have been achieved, from a device which only requires two steps to inhalation and which only has two components plus a dust cover. This makes XCaps highly suited for inhalation applications where minimal training of patients is desirable and has the versatility to treat almost all pulmonary diseases, including asthma, COPD as well as infection, which typically require very large dose delivery. XCaps follows on the heels of another successful Hovione DPI, TwinCaps(R), which was developed specifically for an influenza application and is licensed to Daiichi Sankyo and Biota for this application. Hovione is offering XCaps as a part of its inhalation device portfolio, allowing its integration with a drug product development program, allowing business partners to take their candidate drugs from the API stage all the way to the unit dose, with a single partner.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|